Stock Update (NASDAQ:CYTK): Cytokinetics, Inc. and the ALS Association Announce Awarding of Grant for Phase 3 Clinical Trial and Biomarker Research Collaboration

Cytokinetics, Inc. (NASDAQ:CYTK) and The ALS Association announced that The Association has awarded Cytokinetics a $1.5 million grant to support the collection of clinical data and plasma samples to advance the discovery of biomarkers in ALS (amyotrophic lateral sclerosis) in VITALITY-ALS, a Phase 3 clinical trial of tirasemtiv in patients with ALS.  For the first time, this unique collaboration between Cytokinetics, The ALS Association, and the Barrow Neurological Institutewill enable plasma samples collected from patients enrolled in a Phase 3 clinical trial to be added to The Northeastern ALS Consortium (NEALS) Repository, a resource for the academic research community to identify biomarkers that may help to assess disease progression and underlying disease mechanisms in ALS.

“We are grateful to The ALS Association and everyone who donated to the Ice Bucket Challenge for this grant to assist the funding of VITALITY-ALS and our collaboration withBarrow Neurological Institute for biomarker research,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.  “This collaboration is an extraordinary opportunity to advance the development of tirasemtiv as well as scientific understanding of biomarkers that underlie the progression of ALS at the molecular level.”

“Biomarker discovery is a major priority for ALS research, and we have recently witnessed important progress in this field,” said Lucie Bruijn, Ph.D., M.B.A., Chief Scientist forThe ALS Association. “We are pleased to contribute to this unique collaboration between The Association, industry and academia to progress our shared mission to improve the lives of people living with ALS through the advancement of our knowledge of ALS and through the development of potential novel treatments.”

VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS), which started today, is a multi-national, randomized, double-blind, placebo-controlled trial that is designed to assess the effects of tirasemtiv versus placebo on slow vital capacity  and other measures of respiratory function in patients with ALS.  As part of the trial, plasma samples and longitudinal clinical data will be obtained from participating patients. The clinical information and collected samples will be integrated into the NEALS Repository to support ongoing activities within the scientific community for research on biomarkers from patients with ALS.  VITALITY-ALS is expected to be conducted in more than 75 centers in North America and Europe.

“VITALITY-ALS is the first industry-sponsored clinical trial in which plasma samples from patients with ALS are being collected and shared with the ALS research community,” said Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of VITALITY-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the University of Arizona, Phoenix. “It is especially gratifying when all of our respective interests align to serve our patients living with ALS and their caregivers.” (Original Source)

Shares of Cytokinetics closed yesterday at $6.21. CYTK has a 1-year high of $8.61 and a 1-year low of $3.05. The stock’s 50-day moving average is $6.40 and its 200-day moving average is $6.96.

On the ratings front, Cytokinetics has been the subject of a number of recent research reports. In a report issued on May 13, Roth Capital analyst Joseph Pantginis maintained a Buy rating on CYTK, with a price target of $18, which represents a potential upside of 189.9% from where the stock is currently trading. Separately, on May 1, MLV & Co.’s Vernon Bernardino maintained a Buy rating on the stock and has a price target of $9.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Vernon Bernardino have a total average return of 9.3% and -4.1% respectively. Pantginis has a success rate of 53.5% and is ranked #203 out of 3702 analysts, while Bernardino has a success rate of 40.6% and is ranked #3356.

Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts